We followed a literature search strategy (see supplementary material) to identify manuscripts for inclusion. This identified the antibody isotypes IgG and IgA and their antigen specificities to be of fundamental importance to the subject, and these are presented first in this review. This is followed by a discussion of literature pertaining to maternal antibody transfer and the protection they provide against RSV. Finally, we present current data on prophylactic strategies aiming at improving protection for children, including vaccination and immunoprophylaxis.

Anti-RSV antibodies in infants and adults

In seropositive adults, RSV infection boosts antibody titres via the reactivation of memory B-cells, resulting in elevated anti-RSV immunoglobulin (Ig)M, IgG, and IgA titres [30–32]. Following infection, strong IgG and IgA responses are found to both F and G proteins, but also to N [8, 31, 33]. High titres of anti-RSV IgG and IgA during infection are associated with reduced severity [8, 31]. Anti-RSV IgE was once proposed to predispose individuals to atopy or the development of wheeze and asthma [34, 35], but the existence of anti-RSV IgE and this association have now been refuted [36]. The following sections summarise the literature on the contribution of anti-RSV IgG and IgA to immunity.

IgG

IgG is the main immunoglobulin circulating in adult plasma (∼75% of all antibodies) [37]. Variations in heavy chains and hinge regions define four IgG subclasses (IgG1–4), which all bind antigen but differ in their effector functions [37]. During infection, anti-RSV IgGs bind both F and G [8, 31, 33]; however, neutralising IgGs typically bind epitopes unique to the pre-fusion conformation of F (pre-F) which block virion fusion with target cells [38]. Serum neutralisation titres typically correlate closely with anti-F antibodies (particularly pre-F) [9, 38] with IgG making a dominant contribution due to its abundance in blood; however, diverse isotypes and antigen specificities may also contribute to neutralisation.

Analysing blood IgG titres between acute and convalescent samples revealed that the strongest responses are seen at 13–18 months of life [39]. While boosting of IgG following infection or reinfection was observed in all age groups, the subclass of IgG boosted differs markedly between age groups, where infants induce IgG3 responses absent in adults [39]. As IgG3 has the strongest capacity to induce Fc-effector functions, such as phagocytosis and complement deposition, this age-associated shift in IgG subclasses induced by infection may alter the functions of anti-RSV antibodies over the life course [40]. Indeed, serum from 24-month-old children has been reported to induce weaker natural killer cell activation than that of adults after accounting for differences in antibody titres [41]. At 2–3 weeks post-infection, increases in anti-F IgG are weaker in 0–3-month-old infants relative to 4–6-month-olds, which in turn are weaker than those aged 7–12 months and adults [33, 39, 42]. The plateauing of the blood IgG response to RSV infection from 7 months suggests that this immune response has achieved maturation at this age. IgG1 and IgG3 follow this pattern, whereas IgG2 levels stay low from birth until 19–36 months before increasing until adulthood [39].

IgG titres in blood gradually wane following birth or RSV infection, with one report demonstrating that anti-G and anti-F IgG in RSV-infected 2–4-month-old infants are detected in the serum for 4 months (figure 1) [31]. Together, these reports demonstrate that IgG titres are boosted throughout life due to repeated infections, giving rise to repeated cycles of antibody rising and waning [13, 31], though the IgG subclasses and Fc-mediated effector functions of these repeatedly induced IgGs may change over the life course.

FIGURE 1

Infant blood anti-respiratory syncytial virus (RSV) IgG and IgA titres. Maternally derived IgG is evident in the infant's blood from birth but declines rapidly to undetectable levels around 4 months of age. Following RSV infection, de novo antibody responses occur in infants older than 1–2 months of life, resulting in IgG and IgA titre rises. Created with Biorender.com.

IgA

Monomeric IgA is present in circulation, but IgA is more abundant in mucosal surfaces in a dimeric or multimeric form where it blocks pathogen entry [37]. Variations in hinge regions give rise to two IgA subclasses, IgA1 and IgA2, with IgA2 more frequent in mucosal surfaces whereas IgA1 forms ∼90% of total circulating IgA [37].

IgA induction following RSV infection wanes within 6–12 months in adults and possibly within 2 months in children <2 years [32]. The kinetics of this response may differ from other isotypes [30, 43]. In infants and toddlers aged 0–16 months, anti-RSV IgA are present in nasopharyngeal secretions 2 weeks post-infection [44]. The timing of this nasal IgA response is similar in adults [30, 33], while IgG responses in adults may occur earlier [33]. While these reports support the principle of differing IgA and IgG response kinetics, these studies have not used consistent definitions of infection or methodologies, limiting cross-interpretation [32, 33, 43, 44]. Controlled human infection model studies determined that the robust mucosal IgA responses to infection seen in young adults were absent in older adults, despite similar blood IgG responses [45]. Given the prominent role of mucosal IgA in protection from infection in these models [30], these results indicate that older adults may gain limited protection from each RSV infection and so experience more frequent reinfections [45]. The mechanism behind this weakened IgA response in older adults is unclear, but indicates that the antibody isotypes and subclasses induced by infection and potentially vaccination may change with advancing age.

Differences in mucosal IgA and blood IgG responses to infection in some age groups may indicate differences in memory B-cells expressing different immunoglobulin isotypes [45]. F-specific IgA+ memory B-cells were present in blood samples from some adults at the end of the RSV season [31], but not after experimental infections despite increases in nasal IgA [30]. By contrast, F-specific IgA memory B-cells were not detected in blood from infants or children following RSV infection [31]. Like IgG, IgA may have a protective role, as RSV-infected adults with shorter infection duration (<2 weeks) have higher mucosal anti-G IgA titres [33].

Together, these studies show that IgA, particularly in the mucosa, can protect against RSV infections but that the induction of IgA after RSV infection may be dysregulated, particularly in older adults.

Maternal antibodiesTransplacental transfer of anti-RSV antibodies

To mediate protection, maternal antibodies must first reach the infant's circulation. IgG transfer from maternal to fetal blood depends on crossing both the multinucleated placental syncytiotrophoblasts and fetal capillary endothelial cells [46]. Maternal IgGs are endocytosed by syncytiotrophoblasts, bind neonatal Fc receptors lining the endosome and are transported basolaterally for release into the fetal bloodstream [46].

IgG1 is considered the most transplacentally transferred antibody relative to other isotypes and IgG subclasses, with cord:maternal blood ratios of ∼1.5 [39, 47]. RSV-specific antibodies are similarly transferred, with reports showing cord:maternal ratios between 1.03 and 1.22 [13, 48–50]. Variance in these ratios could be explained by the differing study populations or methodologies employed. Anti-RSV IgG titres decline after birth [39, 51]. The levels of maternally derived IgG required for protection against RSV LRTI is unclear, but this antibody transfer is believed to mediate protection of neonates [48].

The time of gestation when IgG transfer starts is unclear; some studies indicate it begins at 13 weeks’ gestation but only becomes sufficient at 36 weeks, whereas others suggest it begins at 28 weeks [52, 53]. This discrepancy could be explained twofold. Firstly, Fc receptors that mediate transplacental transfer are not abundantly expressed until 26 weeks’ gestation [53]. Secondly, IgG transfer is impeded before 26 weeks by cytotrophoblasts residing under the syncytiotrophoblast layer in the placenta [53]. The timing of mother-to-fetus IgG transfer implies that infants born preterm are vulnerable to RSV, partly due to deficient IgG transfer [54, 55]. In contrast, anti-pre-F IgG transfer does not differ between infants with low birth weight and those with normal birth weight for their gestational age [55].

Infants remain seropositive for maternal anti-RSV antibodies until ∼4–6 months after birth [13, 48, 56, 57]; however, maternal antibodies have a half-life of ∼1 month [13, 49, 53, 56]. Variations in maternal antibody duration between studies could reflect differences in population ethnicity, comorbidities or RSV seasonality. In fact, neutralising antibody half-life in high-income countries (HICs) is ∼1 month whereas in the low- and middle-income countries (LMICs) Kenya and Bangladesh it was ∼2 months, although such differences require formal testing [49, 58]. The decay from seropositivity at birth to seronegativity has been reported at 4.5–4.7 months in two Kenyan cross-sectional studies [58, 59]. However, we must consider that this could be an overestimation of maternal antibody duration, as infections in cross-sectional studies can give the impression of prolonged durability [51]. Birth cohort studies with active surveillance for RSV infection are needed to definitively answer this question. Overall, the evidence indicates that in term-born infants, RSV-specific maternal antibodies start to decline by 2 months of life, reaching seronegativity around 6 months. Far less is known about the presence and durability of these antibodies in preterm infants.

How protective are maternal antibodies?

High cord:maternal blood IgG ratios indicate successful maternal IgG transfer, but the actual amount transferred likely determines protection from RSV disease. One report demonstrated that infants with neutralising antibodies inhibitory concentrations >239 and >60 against RSV-A and RSV-B, respectively, were ∼fourfold more likely to be protected against RSV [60]. Maternal antibodies are associated with protection against RSV hospitalisation in infants <3 months old [10, 49]. Higher maternal serum neutralising antibody titres are associated with lower risk of RSV infection [49], while estimated serum IgG titres at birth were associated with delayed time to first RSV infection [61]. Maternally derived blood anti-pre-F IgG and neutralising antibodies are considered to protect infants from RSV hospitalisation, as lower serum pre-F IgG titres were observed in mothers with infants hospitalised with RSV than those with nonhospitalised infants (23.9 (range 1.4–273.7) µg·L−1 and 30.6 (3.4–220.0) µg·L−1, respectively, p=0.003) [10]. Infants with a serum neutralising antibody titre of 8.0 log2 were three times more likely to be protected from RSV hospitalisation than those with titres <8.0 log2. Together, such studies raise the possibility of establishing a serological correlate of protection for RSV (figure 2) [62, 63].

FIGURE 2

Maternal antibody transfer in preterm, low- and high-titre scenarios. The scale of maternal antibody transfer profoundly influences the scale of antibody transfer to infants. In the scenario of preterm birth, transplacental antibody transfer may be low, resulting in low titres of anti-respiratory syncytial virus (RSV) antibodies in infants and high probability of susceptibility to severe RSV from birth. In maternal low-titre scenarios with term births, transplacental transfer does occur, but may quickly decay below a protective threshold. The amount of antibody needed to achieve this protective threshold is unknown and may be influenced by demographic and environmental factors. In high-titre scenarios, robust transplacental antibody transfer occurs, possibly owing to recent maternal RSV infection or vaccination. These high titres provide a longer window of protection against susceptibility to severe RSV infection. FcRN: neonatal Fc receptor. Created with Biorender.com.

However, some studies refute the possibility of defining a protective threshold. One study of 3646 mother–infant pairs in Nepal found no correlation between cord blood maternal antibody titres and the infant's age at primary RSV infection, suggesting that maternal antibodies did not delay primary RSV infection [50]. Another study reported no significant difference in antibody titres at birth between infants hospitalised with RSV and nonhospitalised, apparently uninfected, controls, though the sample size of 30 RSV cases and 60 controls was small [64]. These studies were conducted in LMIC settings and RSV severity and hospitalisation may be influenced by factors aside from maternal antibodies. An Australian birth cohort study reported that each 10-fold increase in cord blood anti-RSV neutralising antibodies was associated with a 37% decreased risk of RSV-LRTI at 12–24 months of age [65]. This study also reported that higher cord blood RSV neutralising antibody titres were associated with enhanced risk of non-RSV LRTI in 6–12-month-old infants [65]. This result suggested that maternal anti-RSV antibodies may be adversely associated with immunity to other pathogens, but our review found no studies replicating this result. A direct role of anti-RSV antibodies in this association may be unlikely as maternal antibodies have been consistently demonstrated to decay toward seronegativity by 6 months [33, 48, 49, 56–59]. Anti-pre-F IgG in breast milk has also been associated with protection, as mothers of RSV-infected infants aged <6 months had lower breast milk IgG levels than uninfected infants [66]. However, this study did not measure antibody levels in the infants; therefore, the extent of transfer of breast milk antibodies to the infant's plasma is uncertain. Some studies suggest that the presence of maternal antibodies against RSV in infants aged <6 months interferes with the infant's ability to develop a humoral response to RSV, explaining the infant's weak de novo response, though immunological immaturity in infants could also mediate this effect [6, 42, 53, 59].

Many studies highlight the importance of neutralisation as the main correlate of protection for maternally derived antibodies [10, 49, 61, 67]. While many studies report anti-RSV IgG titres, the antigenic targets of these antibodies are crucial. In accordance with the central role of anti-F antibodies in mediating neutralisation, one study reported that IgG anti-N titres in cord blood were not associated with protection from severe LRTI in infants <3 months old [67]. Live virus assays are the gold standard for determining neutralisation, but modern antigens such as pre-F may offer a higher-throughput surrogate [51]. Finally, mucosal antibodies that may be most likely to confer protection from infection [30] are not commonly studied, nor are the subclasses or Fc-dependent effector functions. Together, a majority of studies support a protective role for maternally derived antibodies against hospitalisation with RSV, but less evidence supports protection against acquiring RSV infection. Prevention of disease and prevention of infection may, therefore, be mediated by distinct immunological parameters.

Enhancing protection of infantsImmunoprophylaxis

Infants generate a poor immune response to RSV infection, including a weakened and short-lived memory response, leaving them at risk of severe RSV infection and hindering vaccine development [3, 5, 6]. Passive immunisation approaches have therefore been developed to protect these at-risk infants.

Passive immunoprophylaxis was first achieved with polyclonal RSV hyperimmune globulin (RSV-IGIV) (RespiGam®) [68]. RSV-IGIV prophylaxis trials in groups of at-risk infants demonstrated a 41% risk reduction of RSV-LRTI hospitalisation in infants with bronchopulmonary dysplasia (BPD) or preterm birth [69] and a 31% risk reduction in children with congenital heart disease [70]. The benefit of RSV-IVIG in this latter study was most pronounced in infants <6 months old, where a 58% risk reduction was observed [70]. Contrary to this success as a prophylactic, RSV-IVIG given to previously healthy children during hospitalisation with RSV-LRTI yielded little therapeutic benefit [71]. Together, these studies demonstrated that prophylaxis of at-risk infants could decrease the burden of RSV disease [68].

Coupling the success of RSV-IVIG with an increasing understanding of the importance of anti-F antibodies in neutralisation of RSV led to the development of palivizumab, an anti-F monoclonal IgG with potent in vitro and in vivo activity [72]. Trials of palivizumab in high-risk infants with BPD or preterm birth resulted in a 55% reduction in RSV-LRTI hospitalisation [73]. This was most pronounced in infants born at ≤35 weeks gestation, where a 78% reduction in RSV-LRTI hospitalisation was observed [73]. These studies confirmed the value of anti-RSV prophylaxis, and experimentally demonstrated the protection afforded by systemically delivered IgG anti-RSV-F [68]. The efficacy of palivizumab led to its use in HICs to protect at-risk infants, including preterm infants and young children (≤24 months of age) with haemodynamically significant congenital cardiac disease and/or chronic lung disease. However, meta-analysis of palivizumab cost-effectiveness studies reported that one 100 mg vial cost between USD 904 and 1866 [74], while the US Department of Veteran Affairs lists the maximum price per 100 mg palivizumab dose as USD 2487 (with five doses needed per RSV season) relative to USD 1691 for a 100 mg nirsevimab dose [75]. While considerable variation was noted between studies based on study population and methodology, the cost-effectiveness of palivizumab for preterm infants was estimated at between USD 5188 and 791 265 per quality-adjusted life-year (with 90% of estimates USD <50 000) [74]. These costs proved prohibitive for palivizumab use in many LMICs and limited use to high-risk infants in HICs [74].

With the aim of increasing efficacy and reducing costs, the next-generation monoclonal antibody for RSV immunoprophylaxis, nirsevimab, was developed [76]. Nirsevimab targets the highly conserved antigenic site Ø of RSV pre-F and has >50-fold-higher neutralisation activity than palivizumab [76]. Coupled with substitution of three amino acids in the antibody Fc region (M252Y/S254 T/T256E; “YTE”) that prolong the in vivo half-life to approximately 71 days, this aimed to result in a prophylactic that could be administered as a single-dose, compared to the 5 monthly doses required for palivizumab [74, 76].

Trials in preterm infants demonstrated 78% reduction in RSV-LRTI hospitalisation following a single nirsevimab dose [77]. This was followed by two large-scale multi-centre phase 3 studies; MELODY (1490 healthy infants born ≥35 weeks gestational age with a primary end-point of medically attended RSV associated LRTI) and HARMONIE (8058 infants born ≥29 weeks gestational age with a primary end-point of hospitalisation for RSV-LRTI). In healthy term-born infants, MELODY reported a 62% reduction in RSV-LRTI hospitalisation [78]. Similarly, HARMONIE reported an 83% reduction in RSV-LRTI hospitalisation in infants <12 months old [79]. Together, these studies support the efficacy of nirsevimab in preventing RSV-LRTI. In MELODY, nirsevimab administration increased serum RSV neutralising antibody titres >140-fold at day 31, relative to baseline [80], and titres remained >50-fold above baseline at day 151 [76, 80]. Nirsevimab administration was not associated with a decreased rate of IgG seroconversion to the post-F conformation of RSV-F [80], indicating that RSV infections still occur in nirsevimab-recipient infants but are less severe. Since approval for use in the EU, a real-world population cohort study of 1177 infants determined that nirsevimab was 88.7% effective at preventing RSV hospitalisation [81]. Together, these clinical trials and real-world studies support the effectiveness of immunoprophylaxis in preventing RSV disease in infants.

One theoretical risk of widespread prophylaxis using nirsevimab is selection pressure-led accumulation of binding site mutations that result in escape from neutralisation. To understand the impact of binding site mutations, a metanalysis of 5675 RSV sequences demonstrated that of the 25 amino acids in the nirsevimab binding site, 25 and 22 were highly conserved in RSV-A and RSV-B, respectively [82]. One prevalent RSV-B binding site polymorphism (Ile206Met:Gln209Arg) was still neutralised by nirsevimab, suggesting that while binding site mutations exist and should be monitored, these may have minimal impact on nirsevimab efficacy [82].

In anticipation of nirsevimab licensure, one modelling study estimated the purchasing price per dose of nirsevimab would need to be less than GBP 63 to be cost effective to immunise all infants ahead of the RSV season [83]. Nirsevimab was licensed in the UK and EU in November 2022 and approved by the US Food and Drug Administration in July 2023. Together, immunoprophylactic therapies experimentally confirmed that RSV disease could be prevented by conferring neutralising antibodies to infants in the first months of life, paving the way for next-generation vaccination strategies.

Maternal vaccination

Maternal vaccination confers passive immunity to infants through transplacental transfer of maternal IgG against F, N and G during the third trimester and via breast milk after birth [13, 48–50, 52, 60]. Maternal antibody transfer underpins the success of maternal vaccines, so the quantity of anti-RSV IgG and the time-point of gestation at which IgG is transferred to the fetus are important considerations for maternal vaccine development [84, 85]. As previously described, maternal anti-RSV IgG starts to decline by 2–4 months, with most infants becoming seronegative by 6 months [13, 50, 59]. An infant's immune system is continually maturing, so responses to pathogens and active immunisations in the first months of life may not elicit effective immune responses [19, 50]. This leaves infants vulnerable to severe RSV infection, highlighting the urgency of boosting immunity at birth [4, 5, 13]. Maternal vaccination aims to provide protection against RSV to the infant at birth and prevent severe RSV disease during the first months of life [5] (figure 2). This could also protect the mother, blocking one route of transmission to the infant [10].

Neutralising maternal IgG boosted by RSV vaccine candidates are successfully transplacentally transferred to infants [16–18, 20]; however, like natural infection-derived antibodies, antibody transfer ratios were variable among vaccinees. The Novavax recombinant RSV-F protein nanoparticle maternal vaccine candidate boosted maternal antibody concentrations and demonstrated a transplacental transfer ratio of 1.1–1.2 in infants born >30 days after maternal immunisation versus 0.6–0.8 in those born <30 days after immunisation [16]. This highlights the need to carefully plan maternal immunisation schedules to achieve maximal antibody transfer and benefit. The Pfizer RSV pre-F protein vaccine Abrysvo™ resulted in transfer ratios of 1.41–2.10 [18]. This ratio was higher than the transfer of natural infection induced antibodies, suggesting that transfer after vaccination may be particularly efficient.

One phase I/II study (NCT03674177) of the GSK pre-F3 vaccine demonstrated that a single dose in nonpregnant women increased anti-pre-F IgG neutralising titres 8–14-fold (depending on vaccine dose) 1 week after vaccination, which remained 5–6-fold higher 3 months post-vaccination [84]. The authors acknowledge that they did not account for RSV infections during the study, which may account for increases in antibody titres and confound determination of vaccine immunogenicity. Following this success, a maternal vaccination trial was performed (NCT04126213), showing similar increases in neutralising antibody titres [20]. Transplacental transfer ratios were high (1.62 in the 60 μg dose arm) and maternal antibody titres remained elevated for 6 months [20]. These remaining anti-RSV IgG maternal antibodies may continue to transfer to the infant via breast milk and provide additional protection [66]. The relative vaccine efficacy between breast-fed and nonbreast-fed infants was not reported in these studies but warrants investigation. A phase III trial (NCT04605159) of this vaccine stopped early after an increased rate of preterm birth was observed in vaccinated mothers, relative to placebo (relative risk 1.37) [86].

One Novavax vaccine candidate study demonstrated an efficacy of 44% in reducing RSV-LRTI, 35% in reducing RSV-LRTI hospitalisation and 47% in reducing severe hypoxaemia in the first 3 months of life, although these reported efficacies did not achieve significance in their primary end-point (LRTI in infants after 3 months of birth) [17].

Trials of the Pfizer RSV pre-F maternal vaccine (phase IIb NCT04032093 and phase III NCT04424316) demonstrated reduced risk of RSV-LRTI hospitalisation in the first 6 months of life [18, 19]. The phase IIb trial showed a vaccine efficacy of 91.5% against severe RSV-associated LRTI in the first 6 months of life and 81.8% (99.5% CI; 40.6–96.3) and 69.4% (97.58% CI 44.3–84.1) within 3 and 6 months of life, respectively, in phase III [18, 19]. The decline of vaccine efficacy over time likely reflects waning of maternal antibodies. While efficacy appears promising for Pfizer's RSV vaccine, which has received regulatory approval, some safety concerns have arisen around the potential for increasing rates of preterm birth in vaccinees relative to placebo [87]. While such an effect has not been recapitulated in most studies, the possibility of these risks requires vigilant monitoring and post-marketing surveillance if licenced [88]. Such risks must be balanced against the impact of RSV, with potential risks and benefits communicated to trial participants and patients.

These studies raise important considerations on monitoring vaccine effectiveness. Firstly, paediatric RSV disease will be influenced by the scale of transplacental antibody transfer, which may be lower in LMICs than HICs and in preterm births [17, 18]. Similarly, maternal antibody transfer is less efficient in infants who are small or large for their gestational age; thus, vaccines may be less effective in these high-risk infants [48]. Secondly, breastfeeding may enhance effectiveness through continual provision of maternal antibody, representing a low-cost strategy for RSV prevention that could have a high impact in areas where breastfeeding rates are low [66, 89].

Overall, maternal vaccines have shown promise in successfully transferring maternal antibodies, reducing RSV-LRTI and hospitalisation within 6 months of life. Modelling has demonstrated that maternal vaccination could prevent 62–75% and 76–87% of paediatric intensive care unit admissions with RSV in the UK and Netherlands, respectively, and 29–48% of RSV-related in-hospital deaths worldwide in infants <12 months [90].

Paediatric vaccination

Direct vaccination is considered unlikely to protect infants, owing to the immaturity of immune responses in the first months of life when risk of severe RSV disease is highest [3, 5, 6]. However, passive immunisation only provides transient protection for the first months of life, leaving older infants and toddlers at risk. To meet this gap in immunisation, direct vaccination with a variety of platform technologies approaches are being trialled, including a chimpanzee adenovirus expressing the RSV F, N and M2-1 proteins (e.g. NCT02927873), mRNA (e.g. NCT04528719) and live-attenuated vaccines (e.g. NCT04909021) [91].

While many studies are still ongoing, or yet to report all data, there are promising demonstrations of immunogenicity with these approaches. In one study of 21 seronegative 6–24-month-old infants and toddlers, the nasally administered live-attenuated RSV D46/NS2/N/ΔM2-2-HindIII vaccine induced serum neutralising antibodies in 95% of infants [91]. Immunogenicity was coupled with a high rate of mild upper respiratory tract (URT) symptoms (76% in vaccinees versus 18% in placebo controls), suggesting that a balance between immunogenicity and reactogenicity may be anticipated. A meta-analysis of five live-attenuated RSV vaccine candidates across seven trials indicated that a ≥4-fold rise in serum neutralising antibody titres in response to these vaccines was associated with protection against medically attended RSV infections (odds ratio 0.26) [92]. Interestingly, this analysis found no association between either the detection or scale of vaccine shedding and protection. Given the stronger association between protection and nasal antibodies, relative to blood antibodies [30], it would be of value to study mucosal humoral immune responses in these live-attenuated vaccination studies.

Identifying RSV cases in vaccine efficacy trials

To identify RSV infections in infants enrolled in vaccine efficacy trials, studies typically perform molecular testing for viral RNA during symptomatic episodes [16, 18, 19]. This design captures relative rates of symptomatic disease but does not inform our understanding of paucisymptomatic or asymptomatic infections. Regular viral swab testing outside of symptomatic episodes is burdensome and, depending on frequency and sensitivity, may still miss infections. Serological testing provides an alternative route to capturing RSV infections. Indeed, studies of antibody responses after nirsevimab administration indicate equivalent infection rates between nirsevimab recipients and placebo controls, observed as equal IgG seroconversion to RSV post-F [80]. As maternal vaccination would induce both IgG and IgA against epitopes unique to pre-F (such as site Ø) and common with post-F (such as site 2), but only IgG is transferred transplacentally, infants’ anti-RSV IgA levels have been proposed as a biomarker of RSV infection [51] (figure 1).

One complication is that IgA could be transferred to infants via breast milk [66]. Maternal anti-RSV IgA antibodies may be present in the breast milk, but infant seropositivity depends on if, and how much, IgA is absorbed from the gut to the bloodstream. It has also been proposed that infants might aspirate breast milk into the URT, thus instilling maternal IgA into the airway [93]. Further work is needed to confirm whether infant blood and airway IgA can be maternally derived. Additionally, infections in the first months of life may not trigger antibody responses in infants, so serum IgA-based definitions of RSV infection history may be inaccurate in this age group [42].